← Back to Clinical Trials
Recruiting NCT06542653

NCT06542653 Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06542653
Status Recruiting
Phase
Sponsor The First Affiliated Hospital with Nanjing Medical University
Condition Coronary Atheroscleroses
Study Type OBSERVATIONAL
Enrollment 258 participants
Start Date 2023-09-17
Primary Completion 2024-09-17

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
PCIOMT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 258 participants in total. It began in 2023-09-17 with a primary completion date of 2024-09-17.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Coronary chronic total occlusions (CTOs) are considered to increase the risk of adverse clinical outcomes. The purpose of this study was to evaluate whether long-term clinical outcomes could be improved by successful percutaneous coronary intervention (PCI) over optimal medical therapy (OMT) in CTO patients.

Eligibility Criteria

Inclusion Criteria: * patients with at least one coronary CTO lesion at our hospital in between January 2011 and December 2017 Exclusion Criteria: * (1) patients with ST-segment elevation myocardial infarction (STEMI) * (2)a history of coronary artery bypass grafting (CABG) * (3) cardiogenic shock * (4) malignant tumor. Patients were referred for PCI based on CTO-related symptoms or evidence of viability, or corresponding ischemia in the area of the CTO artery.

Contact & Investigator

Central Contact

Mei Wang

✉ 1513267113@qq.com

📞 0086 15256095215

Principal Investigator

Leilei Chen

STUDY DIRECTOR

The First Affiliated Hospital with Nanjing Medical University

Frequently Asked Questions

Who can join the NCT06542653 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Coronary Atheroscleroses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06542653 currently recruiting?

Yes, NCT06542653 is actively recruiting participants. Contact the research team at 1513267113@qq.com for enrollment information.

Where is the NCT06542653 trial being conducted?

This trial is being conducted at Nanjing, China.

Who is sponsoring the NCT06542653 clinical trial?

NCT06542653 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Leilei Chen at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 258 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology